US Patent

US9440922 — Tetracyclic compound

Formulation · Assigned to Chugai Pharmaceutical Co Ltd · Expires 2030-06-09 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a compound represented by Formula (I), useful as an ALK inhibitor for treating or preventing diseases like cancer.

USPTO Abstract

A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).

Drugs covered by this patent

Patent Metadata

Patent number
US9440922
Jurisdiction
US
Classification
Formulation
Expires
2030-06-09
Drug substance claim
No
Drug product claim
Yes
Assignee
Chugai Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.